Ardelyx, Inc. Common Stock Offering
Davis Polk advised the joint book-running managers in connection with an $86.2 million SEC-registered follow-on common stock offering of 8,625,000 shares of common stock for Ardelyx, Inc…
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Adamas Pharmaceuticals, Inc. Common Stock Offering
Davis Polk advised the joint book-running managers in connection with a $66.1 million SEC-registered common stock offering of 2,875,000 shares of common stock of Adamas Pharmaceuticals, Inc…
Cempra, Inc. Common Stock Offering
Davis Polk advised the underwriters in connection with the SEC-registered offering of 4,166,167 shares of common stock of Cempra, Inc. The net proceeds to Cempra were approximately $93.7…
Mylan N.V. $1 Billion Notes Offering
Davis Polk advised the representatives of the initial purchasers on two Rule 144A/Regulation S offerings by Mylan N.V. of $500 million aggregate principal amount of its 3.000% senior notes…
Davis Polk Advises Penumbra, Inc. on Its $138 Million Initial Public Offering
Davis Polk advised Penumbra, Inc. on its SEC-registered initial public offering of 4,600,000 shares of common stock for an aggregate price to the public of approximately $138 million,…
Seattle Genetics, Inc. $552 Million Equity Offering
Davis Polk advised the underwriters, in connection with an SEC-registered offering by Seattle Genetics, Inc. of 13,463,415 shares of common stock, which includes 1,756,097 shares of common…
Biogen Inc. $6 Billion Senior Notes Offering
Davis Polk advised the underwriters, in connection with the SEC-registered offering by Biogen Inc. of $1.5 billion principal amount of 2.900% senior notes due 2020, $1.0 billion principal…
Global Blood Therapeutics, Inc. Initial Public Offering
Davis Polk advised the joint book-running managers in connection with the $138 million initial public offering of common stock of Global Blood Therapeutics, Inc. Global Blood’s common stock…
Celgene $8.0 Billion Notes Offering
Davis Polk advised the joint book-running managers on an SEC-registered offering by Celgene Corporation of $8.0 billion aggregate principal amount of notes. The notes were issued in…
Aimmune Therapeutics, Inc. $183.9 Million Initial Public Offering
Davis Polk advised the underwriters in connection with the $183.9 million initial public offering of Aimmune Technologies, Inc. Aimmune Therapeutics sold 11,499,999 shares of its…